A 6-year-old girl from rural Maharashtra presents with a 2-month history of progressive fatigue, recurrent infections, and bleeding gums. On examination, she has severe pallor, gingival hypertrophy with bleeding, petechiae, and lymphadenopathy (cervical and axillary nodes 2–3 cm). Laboratory findings: Hemoglobin 5.8 g/dL, WBC 120,000/μL (80% blasts with abundant Auer rods), platelets 28,000/μL. Bone marrow shows >90% blasts with abundant cytoplasmic granules and Auer rods. Flow cytometry: CD13+, CD33+, MPO+, HLA-DR+. Cytochemistry: Sudan black positive. What is the most likely diagnosis?

Explanation

## Clinical Diagnosis: Acute Promyelocytic Leukemia (APL, AML-M3) ### Diagnostic Criteria **Key Point:** This case presents the classic morphologic, cytochemical, and immunophenotypic features of Acute Promyelocytic Leukemia (APL, FAB M3). APL is a distinct subtype of AML characterized by abnormal hypergranular promyelocytes, abundant Auer rods (often in "faggot" bundles), and a strong tendency for coagulopathy. ### Morphologic and Cytochemical Evidence | Finding | Significance | |---------|---------------| | Auer rods (abundant) | Hallmark of APL; faggot cells (multiple Auer rods per blast) are pathognomonic for M3 | | Abundant cytoplasmic granules | Hypergranular promyelocytes — defining feature of APL (M3) | | Sudan black positive | Confirms myeloid lineage; strongly positive in APL | | >90% blasts in marrow | Diagnostic for acute leukemia | | Gingival hypertrophy + bleeding | Tissue infiltration by leukemic cells; bleeding also driven by DIC in APL | ### Immunophenotype Analysis **High-Yield:** The flow cytometry panel is consistent with APL: - **CD13+, CD33+** — myeloid-associated antigens; strongly expressed in APL - **MPO+** — myeloperoxidase; intensely positive in APL due to abundant granules - **HLA-DR+** — while APL classically shows HLA-DR negativity, HLA-DR positivity does NOT exclude APL, particularly in the microgranular (M3v) variant or in cases with partial expression; the overall morphologic and cytochemical picture takes precedence - **Sudan black strongly positive** — characteristic of APL ### Why APL (M3) and NOT AML-M2? **Warning:** The critical distinguishing features in this case point to APL (M3), not M2: | Feature | **APL (M3)** | AML-M2 | |---------|---|---| | Auer rods | **Abundant / faggot cells** | Present but less numerous | | Cytoplasmic granules | **Hypergranular (abundant)** | Present but less prominent | | Cytogenetics | **t(15;17); PML-RARA** | t(8;21) most common | | HLA-DR | Typically negative (but variable) | Positive | | Coagulopathy/DIC | **Characteristic** | Absent | | Sudan black | Strongly positive | Positive | | Maturation | Abnormal promyelocytes | >10% mature myeloid forms | **Key Point:** The combination of **abundant Auer rods + hypergranular blasts + MPO strongly positive + Sudan black positive** in a child with bleeding is the textbook picture of APL (M3). AML-M2 does have Auer rods but they are not described as "abundant" with "abundant cytoplasmic granules" filling the cytoplasm. ### Clinical Pearl: APL and Bleeding **Clinical Pearl:** APL is the AML subtype most strongly associated with life-threatening coagulopathy (DIC + fibrinolysis). The gingival bleeding and petechiae in this case reflect both thrombocytopenia and the coagulopathy characteristic of APL. Prompt recognition is critical because APL is treated with **All-Trans Retinoic Acid (ATRA) + arsenic trioxide**, which is distinct from standard AML chemotherapy. ### Why NOT AML-M2 (Option B)? The original answer of M2 is incorrect because: 1. **Abundant Auer rods with abundant cytoplasmic granules** is the hallmark of M3, not M2 2. M2 is characterized by maturation (>10% differentiated myeloid forms), which is not described here — the marrow shows >90% blasts with granular morphology consistent with promyelocytes 3. The clinical bleeding tendency (gingival bleeding, petechiae) combined with hypergranular blasts strongly favors APL ### Treatment Approach **Key Point:** APL is uniquely treated with: 1. **ATRA (All-Trans Retinoic Acid)** — targets PML-RARA fusion protein, induces differentiation 2. **Arsenic trioxide (ATO)** — synergistic with ATRA; standard of care in low/intermediate risk APL 3. **Anthracycline-based chemotherapy** — for high-risk APL (WBC >10,000/μL) 4. Urgent management of DIC/coagulopathy with FFP, cryoprecipitate, platelets [cite: Harrison's Principles of Internal Medicine 21e Ch 110; Lanzkowsky Pediatric Hematology-Oncology 6e Ch 11; Robbins & Cotran Pathologic Basis of Disease 10e Ch 13]